@article{ce43fdd6946c4dd982565760c3d7fdb0,
title = "PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway",
abstract = "Mixed lineage leukemia (MLL) fusion proteins directly activate the expression of key downstream genes such as MEIS1, HOXA9 to drive an aggressive form of human leukemia. However, it is still poorly understood what additional transcriptional regulators, independent of the MLL fusion pathway, contribute to the development of MLL leukemia. Here we show that the transcription factor PU.1 is essential for MLL leukemia and is required for the growth of MLL leukemic cells via the promotion of cell-cycle progression and inhibition of apoptosis. Importantly, PU.1 expression is not under the control of MLL fusion proteins. We further identified a PU.1-governed 15-gene signature, which contains key regulators in the MEIS-HOX program (MEIS1, PBX3, FLT3, and c-KIT). PU.1 directly binds to the genomic loci of its target genes in vivo, and is required to maintain active expression of those genes in both normal hematopoietic stem and progenitor cells and in MLL leukemia. Finally, the clinical significance of the identified PU.1 signature was indicated by its ability to predict survival in acute myelogenous leukemia patients. Together, our findings demonstrate that PU.1 contributes to the development of MLL leukemia, partially via crosstalk with the MEIS/HOX pathway.",
keywords = "MEIS1, MLL leukemia, PU.1, transcription regulation",
author = "J. Zhou and J. Wu and B. Li and D. Liu and J. Yu and X. Yan and S. Zheng and J. Wang and L. Zhang and L. Zhang and F. He and Q. Li and A. Chen and Y. Zhang and X. Zhao and Y. Guan and X. Zhao and J. Yan and J. Ni and Nobrega, {M. A.} and B. L{\"o}wenberg and R. Delwel and Valk, {P. J.M.} and A. Kumar and L. Xie and Tenen, {D. G.} and G. Huang and Wang, {Q. F.}",
note = "Funding Information: We thank Drs Jose Cancelas, H Leighton Grimes, James Mulloy, Susumu Goyama (Cincinnati Children{\textquoteright}s Hospital Medical Center) and Frank Rosenbauer (Max Delbr{\"u}ck Center for Molecular Medicine) for their critical reading and valuable comments on the manuscript. We also thank Tami R Bartell for English editing. This study was supported by the Hundred Talents Program of the Chinese Academy of Sciences (to QFW), the National Natural Science Foundation of China grants No. 81070442 and No. 91331111 (to QFW), No. 81100381 (to JZ), No. 81300438 (to JW) and the {\textquoteleft}Strategic Priority Research Program{\textquoteright} of the Chinese Academy of Sciences (to QFW), No. XDA01010305. This work was also supported in part by the Knowledge Innovation Program of the Chinese Academy of Sciences (to FHH) and sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry (to QFW). We would like to acknowledge support from the Cincinnati Children{\textquoteright}s Hospital Research Foundation, the Ohio Cancer Research Associates, the Cancer Free Kids, the Leukemia Research Foundation and the Pilot Research Grant of the State Key Laboratory of Experimental Hematology (Tianjin, China) (to GH), the NIH grant HL112719 (to DGT) and NIH grant HL111192 (to AK).",
year = "2014",
month = jul,
doi = "10.1038/leu.2013.384",
language = "English (US)",
volume = "28",
pages = "1436--1448",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Springer Nature",
number = "7",
}